en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6608.com › Blog › Identity And Molecular Background — Research Overview

Identity And Molecular Background — Research Overview

By Editorial Desk · published 2026-04-16 · last reviewed 2026-05-30 · Blog

peptide storage comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-05-30. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Molecular Background

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.

分子身份与天然来源

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular formulaC129H215N33O55Calculated for the acetylated 28-residue peptide
AppearanceWhite to off-white powderLyophilized solid recovered from aqueous buffer
SolubilityFreely soluble in waterTypically dissolved in water or buffer before use
Typical storage-20 C or below, desiccatedProtect from light and avoid repeated freeze-thaw cycles
Identity testingReverse-phase HPLC with mass spectrometryRetention time and measured mass confirm the sequence

Storage, Handling and Analytical Verification

Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.

Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.

Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.

Related pages on this site

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Background and Biological Role

The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.

The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.

Background, Structure, and Mechanism

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Further detail

=== Vaccines === The cold chain is used in the supply of vaccines to distant clinics in hot climates served by poorly developed transport networks. Disruption of a cold chain due to war or logistical challenges may produce severe consequences, as distributed vaccines can become inert due to a lack of temperature control during transport. The integrity of the vaccine cold chain is therefore a critical public health concern. For vaccines, there are different types of cold chains. There is an ultralow, or deep freeze, cold chain for vaccines that require -70 degrees C, such as the Ebola and Pfizer–BioNTech COVID-19 vaccines, and some animal vaccines. Next the frozen chain requires -20 degrees C. Varicella and zoster vaccinations require this level. Then the refrigerated chain, which requires temperatures between two and eight degrees C. Most flu vaccinations only require refrigeration. In 2020, during the COVID-19 pandemic, vaccines being developed may need ultracold storage and transportation temperatures as cold as −70 °C (−94 °F), requiring what has been referred to as a "colder chain" infrastructure. This creates some issues of distribution for the Pfizer vaccine. It is estimated that only 25 to 30 countries in the world have the infrastructure for the required ultracold cold chain.

Warships, as an example, are designed to revel in controlled destruction; seeing a certain glory in achieving a 'worthwhile' death also seems characteristic. The presence of human crews on board warships may discourage such recklessness, since in the normal course of things, a Mind would not risk beings other than itself. With their almost godlike powers of reasoning and action comes a temptation to bend (or break) Cultural norms of ethical behaviour, if deemed necessary for some greater good. In The Player of Games, a Culture citizen is blackmailed, apparently by Special Circumstances Minds, into assisting the overthrow of a barbaric empire, while in Excession, a conspiracy by some Minds to start a war against an oppressive alien race nearly comes to fruition. Yet even in these rare cases, the essentially benevolent intentions of Minds towards other Culture citizens is never in question. More than any other beings in the Culture, Minds are the ones faced with the more complex and provocative ethical dilemmas.

With the increase in commercial alligator farming in countries including Thailand, the United States, Australia, South Africa, and South East Asia, crocodile fat and oil became a commercial product that can be used in a number of ways such as medicine, skin care products, and as a feedstock for biodiesel. Natural oils are extensively used in cosmetics and as treatment for a growing number of conditions. According to Vermaak, the natural products industry is a multibillion-dollar industry and has grew enormously in the years up to 2011. Crocodile oil as an oil mainly containing fatty acids contribute to beneficial properties in cosmetics and personal care products. More specifically, crocodile oil is also used in the tanning industry. The oil can range from about $US4 for a tube of crocodile lip balm to about $US104 for a large jar of pure crocodile oil balm. Businesses consider the capability to convert crocodile fat to a marketable oil. They can capitalise on "first-mover advantage" due to crocodile oil benefits. Golden 8 Skincare is an Australian company, using crocodile oil as the main ingredient of its product. The company's description of the product include "Packed full of Omegas 3,6 7 and 9 to help in the healing of skin conditions due to its Natural Moisturising Factor (NMF) Crocodile Oil helps prevents dermal irritation and regenerates the skin whilst providing the skin its daily dose of Omegas to produce clear, glowing, healthy skin." Crocodile oil lotions and other products derived from crocodile fat can be seen sold online for personal use.

The two substrates of this enzyme are (R)-3-hydroxybutyric acid and oxidised nicotinamide adenine dinucleotide (NAD+}. Its products are acetoacetic acid, reducad NADH, and a proton. This enzyme belongs to the family of oxidoreductases, to be specific, those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. This enzyme participates in the synthesis and degradation of ketone bodies and the metabolism of butyric acid.

Sources: en.wikipedia.org

Supporting material

The prevalence of undernutrition is highest among children under five. In 2024, 150.2 million children under five years old were stunted, 42.8 million were wasted, and 35.5 million were overweight or obese. In 2021, an estimated 45% of deaths in children were linked to undernutrition. As of 2020, the prevalence of wasting among children under five in South Asia was reported to be 16% moderately or severely wasted. As of 2022, UNICEF reported this prevalence as having slightly improved, but still being at 14.8%. India has one of the highest burdens of wasting in Asia with over 20% wasted children. However, the burden of undernutrition among under-five children in African countries is much higher. A pooled analysis of the prevalence of chronic undernutrition among under-five children in East Africa was identified to be 33.3%. This prevalence of undernutrition among under-five children ranged from 21.9% in Kenya to 53% in Burundi. In Tanzania, the prevalence of stunting, among children under five varied from 41% in lowland and 64.5% in highland areas. Undernutrition by underweight and wasting was 11.5% and 2.5% in lowland and 22.% and 1.4% in the highland areas of Tanzania respectively. In South Sudan, the prevalence of undernutrition explained by stunting, underweight and wasting in under-five children were 23.8%, 4.8% and 2.3% respectively. In 28 countries, at least 30% of children were still affected by stunting in 2022. Vitamin A deficiency affects one third of children under age 5 around the world, leading to 670,000 deaths and 250,000–500,000 cases of blindness.

Hudson, John, Normans, BBC. Dudo of St. Quentin, Gesta Normannorum, The orb, English translation. Breve Chronicon Northmannicum (in Latin), Storia online. The Normans (PDF), Jersey heritage trust, archived from the original (PDF) on 26 March 2009. The Normans in Italy (in Italian), MondoStoria, archived from the original on 1 September 2017, retrieved 14 May 2015. Freeman, Edward Augustus (1911). "Normans" . Encyclopædia Britannica. Vol. 19 (11th ed.). pp. 751–756.

The two opposing glutamates add and subtract protons from C1 and C2 and their respective oxygens, O1 and O2. The first half of the reaction transfers a proton from C1 to O2, whereas the second half transfers a proton from O1 to C2. The former reaction may be carried out by either of the opposing glutamates, depending on the initial chirality of C1 in the hemithioacetal substrate; however, the second half is stereospecific and is carried out by only one of the opposing glutamates. It is worthy to note that the first theoretically confirmed mechanism for the R-substrate of glyoxalase one published recently. The catalytic mechanism of Glyoxalase has been studied by density functional theory, molecular dynamics simulations and hybrid QM/MM methods. The reason for the special specificity of the enzyme (it accepts both enantiomers of its chiral substrate but converts them to the same enantiomer of the product) is the higher basicity and flexibility of one of the active site glutamates (Glu172).

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1?

It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.

Is thymosin alpha 1 the same as thymosin beta 4?

No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.

How is the peptide obtained for laboratory work?

Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.

胸腺素α1是激素吗?

它不是经典的内分泌激素,而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现,而非经血液循环作用于远隔器官。

Network